PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50324F63003Oseltamivir phosphate 75mg 10 CT blister — Alvogen Inc

Alvogen Inc holds $284.8M across 11 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 75A50119D00035. Competition previously drew 8 offers. Recompete timing centers on the Sep 28, 2027 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Alvogen Inc

Recipient

Sep 28, 2027

PoP end

$74.5M

Obligated

325412

NAICS

6505

PSC

8 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal

Contract number75A50324F63003

Also listed as75A50119D00035-75A50324F63003

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentAlvogen Inc

UEILJNNGDV77Y98

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV75A50119D00035

Place of performanceMORRISTOWN, NJ

Related solicitation75A3234Q00019

PoP end (current)Sep 28, 2027

Obligated$74.5M

OSELTAMIVIR PHOSPHATE 75MG, 10 CT BLISTER (ADULT COURSE) is a federal award for Aspr/Orm-Sns held by Alvogen Inc. Estimated value $74.5M ($74.5M obligated). Current period of performance ends Sep 28, 2027. Last award drew 8 bidders. Place of performance: MORRISTOWN, NJ. Related solicitation 75A3234Q00019.

OSELTAMIVIR PHOSPHATE 75MG, 10 CT BLISTER (ADULT COURSE)

Recompete timing

Public

● Expiring in 361 days

Current PoP ends Sep 28, 2027 (361 days remaining). Agencies typically plan 12–18 months ahead — at 11.9 months out, that window is already open. The buying decision is likely already in motion.

Want the durability read on 75A50324F63003? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Alvogen Inc — $284.8M obligated across 11 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$284.8M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

75A50325F80013

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAM…

$227.7M

Jun 29, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50324F63003?

75A50324F63003 (Oseltamivir phosphate 75mg 10 CT blister) is a Aspr/Orm-Sns award with an estimated value of $74.5M, currently held by Alvogen Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50324F63003?

Aspr/Orm-Sns awarded 75A50324F63003 to Alvogen Inc.

Who is the incumbent on 75A50324F63003?

Alvogen Inc is the incumbent with $284.8M across 11 related awards in SCOUT’s public footprint. The current period of performance ends Sep 28, 2027.

When does Alvogen Inc’s 75A50324F63003 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 28, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50324F63003? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Apr 11, 2025